On Invalid Date, Bridgebio Pharma (NASDAQ: BBIO) reported Q4 2023 earnings per share (EPS) of -$0.96, up 4.35% year over year. Total Bridgebio Pharma earnings for the quarter were -$168.15 million. In the same quarter last year, Bridgebio Pharma's earnings per share (EPS) was -$0.92.
As of Q2 2024, Bridgebio Pharma's earnings has grown year over year. Bridgebio Pharma's earnings in the past year totalled -$643.20 million.
What is BBIO's earnings date?
Bridgebio Pharma's earnings date is Invalid Date. Add BBIO to your watchlist to be reminded of BBIO's next earnings announcement.
What was BBIO's revenue last quarter?
On Invalid Date, Bridgebio Pharma (NASDAQ: BBIO) reported Q4 2023 revenue of $1.75 million up 6.68% year over year. In the same quarter last year, Bridgebio Pharma's revenue was $1.87 million.
What was BBIO's revenue growth in the past year?
As of Q2 2024, Bridgebio Pharma's revenue has grown -88.02% year over year. This is 241.87 percentage points lower than the US Biotechnology industry revenue growth rate of 153.85%. Bridgebio Pharma's revenue in the past year totalled $9.30 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.